BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA® Biotech Investing
vTv Therapeutics Presents Additional Positive Data from the Phase 2 Simplici-T1 Study Biotech Investing
BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia Biotech Investing
